INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

July 24, 2024

https://www.globenewswire.com/news-release/2024/07/23/2917232/0/en/INmune-Bio-Inc-Publishes-Novel-Biology-on-Natural-Killer-Cancer-Immunotherapy-INKmune-in-the-Journal-for-ImmunoTherapy-of-Cancer.html

Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics

BOCA RATON, Fla., July 23, 2024 (GLOBE NEWSWIRE) — — INmune Bio Inc. (NASDAQ:INMB) (the “Company”), a clinical-stage inflammation and immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the publication of our landmark paper in Journal Immunotherapy of Cancer co-authored by Mark Lowdell, PhD, INmune’s Chief Scientific Officer, titled,  “ Proteomic and phenotypic characteristics of memory-like Natural Killer cells for cancer immunotherapy.” Link to paper: https://jitc.bmj.com/content/12/7/e008717

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.